Compare NTAP & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTAP | IQV |
|---|---|---|
| Founded | 1992 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Electronic Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 34.6B |
| IPO Year | 1996 | 2013 |
| Metric | NTAP | IQV |
|---|---|---|
| Price | $165.63 | $207.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $116.58 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 11.99 | 4.67 |
| EPS | ★ 6.35 | 1.61 |
| Revenue | $6,237,000,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $6.22 | $6.77 |
| Revenue Next Year | $4.91 | $5.89 |
| P/E Ratio | ★ $25.78 | $127.99 |
| Revenue Growth | 5.59 | ★ 41.60 |
| 52 Week Low | $93.69 | $154.50 |
| 52 Week High | $192.83 | $247.05 |
| Indicator | NTAP | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 72.74 |
| Support Level | $95.25 | $159.91 |
| Resistance Level | $192.83 | $209.48 |
| Average True Range (ATR) | 6.46 | 6.81 |
| MACD | -0.92 | 2.88 |
| Stochastic Oscillator | 88.78 | 92.51 |
NetApp Inc is storage hardware provider into a software-driven, cloud-centric data infrastructure company. Its flagship ONTAP data management software, together with a comprehensive portfolio of all-flash, hybrid-flash, and cloud-native solutions, forms the backbone of digital transformation for thousands of enterprises world'wide. Its operations are organized into two segments Hybrid Cloud and Public Cloud. It generates majority of revenue from Hybrid Cloud offers a unified data storage portfolio of storage management and infrastructure solutions that helps customers modernize their data centers. Hybrid Cloud includes software, hardware, and related support, along with professional and other services. It generates majority of revenue from United States followed by International market.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.